peterschreiber.media
Regeneron (REGN) has announced a failure in a late-stage trial designed to evaluate a combination therapy involving its anti-PD-1 immunotherapy Libtayo against pembrolizumab, Merck’s (MRK) blockbuster cancer therapy marketed as Keytruda.
The Phase 3 study evaluated Regeneron’s (REGN) fianlimab
